XBP1 and urinary bladder cancer: Moreover, Chen et al. revealed that suppressing the interaction between XBP1-s and the promoter region of β-catenin using CYD6-17, an oridonin analogue, can efficiently reduce the expression of β-catenin, and subsequently suppress the growth of the drug-resistant muscle-invasive bladder cancer cells [103].